JW SHINYAK CORPORATION Logo

JW SHINYAK CORPORATION

Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.

067290 | KO

Overview

Corporate Details

ISIN(s):
KR7067290007
LEI:
Country:
South Korea
Address:
경기도 과천시 과천대로7길 38 -, 과천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

JW Shinyak Corporation is a pharmaceutical company that operates as a specialized maker for the clinical market. The company develops, produces, and supplies high-quality specialty medicines and medical supplies, with a primary focus on the fields of dermatology, urology, and otolaryngology. Committed to research and development, JW Shinyak aims to develop innovative new drugs through advanced medical technology, including its proprietary "DC vacuum technology" and "CTP". The company's product portfolio includes treatments for conditions such as androgenic alopecia (hair loss), endocrine disorders, and various bacterial infections.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-01 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1015.4 KB
2025-05-08 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.7 KB
2025-03-19 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.7 MB
2025-03-18 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 474.4 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 25.9 KB
2025-02-25 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.2 KB
2025-02-25 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 95.3 KB
2025-02-25 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 96.4 KB
2025-02-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.4 KB
2025-02-07 00:00
Regulatory News Service
주식등의대량보유상황보고서(일반)
Korean 74.0 KB
2025-02-07 00:00
Regulatory News Service
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.2 KB
2025-02-07 00:00
Regulatory News Service
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB

Automate Your Workflow. Get a real-time feed of all JW SHINYAK CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JW SHINYAK CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JW SHINYAK CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.